8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 23, 2019)

Filed July 23, 2019For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) announced its second quarter 2019 financial results via a press release filed on July 23, 2019. This 8-K filing primarily serves to incorporate by reference the detailed financial information provided in the accompanying press release (Exhibit 99.1). Investors should refer to this press release for specific details on the company's performance during the quarter, including revenue, earnings, and any forward-looking guidance. The release of Q2 2019 financial results is a significant event for investors as it provides an update on the company's operational and financial health. Key metrics such as sales growth in its core transcatheter aortic valve replacement (TAVR) and critical care segments, profitability, and any changes to full-year financial outlook are critical for evaluating the company's trajectory and making informed investment decisions.

Key Highlights

  • 1Edwards Lifesciences filed an 8-K on July 23, 2019, to report its Q2 2019 financial results.
  • 2The press release containing the Q2 2019 financial results is furnished as Exhibit 99.1.
  • 3The filing incorporates the press release by reference, making it an integral part of the report.
  • 4Investors are directed to the press release for detailed financial performance information.
  • 5The report covers results for the second quarter of 2019.
  • 6Information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally report and incorporate by reference Edwards Lifesciences' financial results for the second quarter of 2019, as detailed in the accompanying press release (Exhibit 99.1).

The detailed financial results for the second quarter of 2019 can be found in the press release, which is furnished as Exhibit 99.1 to this 8-K filing and is incorporated by reference.

Investors should look for key financial metrics such as revenue growth (particularly in TAVR and critical care segments), earnings per share (EPS), net income, gross margins, operating expenses, and any updated guidance or outlook for the full fiscal year 2019.

This 8-K filing itself does not contain new guidance. The guidance for the full year 2019, if any, would be included within the press release (Exhibit 99.1) that is incorporated by reference.